ReviewFrontiers in pharmacology2016
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Analysis of Normalizers and Neurodevelopment-Related microRNAs in the Prefrontal Cortex and in the Sperm of SHR Rats.International journal of molecular sciences · 2025Article
- Association of TRPV1 and the SIRT3/SOD2 Signaling Pathway in Mononuclear Cells and Astrocyte-Derived Extracellular Vesicles in Patients with Schizophrenia.Brain sciences · 2025Article
- Capsaicin alleviates neuronal apoptosis and schizophrenia-like behavioral abnormalities induced by early life stress.Schizophrenia (Heidelberg, Germany) · 2023Article
- MAM-2201 acute administration impairs motor, sensorimotor, prepulse inhibition, and memory functions in mice: a comparison with its analogue AM-2201.Psychopharmacology · 2023Article
- Neuroinflammation in early, late and recovery stages in a progressive parkinsonism model in rats.Frontiers in neuroscience · 2022Article
- Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.Psychopharmacology · 2021Article
- Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.Frontiers in pharmacology · 2021Review
- Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update.Current neuropharmacology · 2021Review
- Effects of combined 5-HTPsychopharmacology · 2020Article
- Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?Frontiers in pharmacology · 2020Review
- Cannabidiol does not display drug abuse potential in mice behavior.Acta pharmacologica Sinica · 2019Article
- Pharmacological and Behavioral Effects of the Synthetic Cannabinoid AKB48 in Rats.Frontiers in neuroscience · 2019Article
- Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.British journal of pharmacology · 2018Article
- Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.CNS neuroscience & therapeutics · 2018Article
- An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.Cannabis and cannabinoid research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gating functioning and is impaired in schizophrenia patients as well as in animal models of this disorder. Recent data point to the participation of the endocannabinoid system in the pathophysiology and pharmacotherapy of schizophrenia. Here, we focus on the effects of cannabinoid drugs on the PPI deficit of animal models of schizophrenia, with greater focus on the SHR (Spontaneously Hypertensive Rats) strain, and on the future prospects resulting from these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.